Trial Profile
Hepatitis C viral dynamics and immune activation in HCV / HIV co-infected patients during treatment with pegylated interferon alpha-2a and ribavirin.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2012
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; HIV infections
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 05 Dec 2012 New trial record